7.15
price up icon33.40%   1.79
after-market After Hours: 7.09 -0.06 -0.84%
loading
Ataibeckley Inc stock is traded at $7.15, with a volume of 165.66M. It is up +33.40% in the last 24 hours and up +72.71% over the past month. AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
See More
Previous Close:
$5.36
Open:
$7.065
24h Volume:
165.66M
Relative Volume:
16.53
Market Cap:
$2.63B
Revenue:
$3.49M
Net Income/Loss:
$-663.48M
P/E Ratio:
-3.1938
EPS:
-2.2387
Net Cash Flow:
$-115.08M
1W Performance:
+34.15%
1M Performance:
+72.71%
6M Performance:
+96.43%
1Y Performance:
+164.81%
1-Day Range:
Value
$7.02
$7.22
1-Week Range:
Value
$4.81
$7.22
52-Week Range:
Value
$2.67
$7.22

Ataibeckley Inc Stock (ATAI) Company Profile

Name
Name
Ataibeckley Inc
Name
Phone
1 929 207 2670
Name
Address
C/O ATAI LIFE SCIENCES US, INC., NEW YORK
Name
Employee
99
Name
Twitter
Name
Next Earnings Date
2026-08-13
Name
Latest SEC Filings
Name
ATAI's Discussions on Twitter

Compare ATAI vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ATAI icon
ATAI
Ataibeckley Inc
7.15 1.97B 3.49M -663.48M -115.08M -2.2387
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
486.03 121.09B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
678.94 69.66B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
857.97 53.99B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
179.18 39.21B 742.00K -1.37B -1.07B -7.0731
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
283.15 37.27B 4.29B 577.22M 641.34M 4.2086

Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-27-26 Initiated Deutsche Bank Buy
Jan-20-26 Initiated Guggenheim Buy
Oct-13-25 Initiated Needham Buy
Jul-29-25 Initiated Oppenheimer Outperform
Nov-18-24 Reiterated H.C. Wainwright Buy
Apr-03-24 Upgrade Maxim Group Hold → Buy
Nov-01-22 Initiated Loop Capital Buy
Nov-30-21 Initiated Maxim Group Buy
Nov-11-21 Initiated ROTH Capital Buy
Oct-18-21 Initiated H.C. Wainwright Buy
Sep-01-21 Initiated Jefferies Buy
Jul-13-21 Initiated Berenberg Buy
Jul-13-21 Initiated Canaccord Genuity Buy
Jul-13-21 Initiated Cantor Fitzgerald Buy
Jul-13-21 Initiated Citigroup Buy
Jul-13-21 Initiated Cowen Outperform
Jul-13-21 Initiated Credit Suisse Outperform
Jul-13-21 Initiated RBC Capital Mkts Sector Perform
Jul-08-21 Initiated Aegis Capital Buy
View All

Ataibeckley Inc Stock (ATAI) Latest News

pulisher
Jul 16, 2026

AtaiBeckley (ATAI) Agrees To Eli Lilly Buyout With Milestone Upside For Shareholders - simplywall.st

Jul 16, 2026
pulisher
Jul 16, 2026

Why Did AAPL, ATAI, UNH Stocks Jump To 52-Week Highs Today? - Stocktwits

Jul 16, 2026
pulisher
Jul 16, 2026

Eli Lilly (LLY.US) invests $3.8 billion to enter the psychedelic drug sector! Acquires AtaiBeckley (ATAI.US) with a 26% premium - Bitget

Jul 16, 2026
pulisher
Jul 16, 2026

AtaiBeckley (ATAI) Soars to 4-Year High on $3.8B Merger with Eli Lilly - Yahoo Finance UK

Jul 16, 2026
pulisher
Jul 16, 2026

Why AtaiBeckley Stock Soared Today - The Motley Fool

Jul 16, 2026
pulisher
Jul 16, 2026

Are ATAI, FHB, PATK Obtaining Fair Deals for their Shareholders? - Morningstar

Jul 16, 2026
pulisher
Jul 16, 2026

Why AtaiBeckley Stock Soared Today - The Motley Fool

Jul 16, 2026
pulisher
Jul 16, 2026

Lilly offers up to $3.8 billion for AtaiBeckley in bet on ‘God molecule’ found in toad venom - drugdiscoverytrends.com

Jul 16, 2026
pulisher
Jul 16, 2026

Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billion - The Motley Fool

Jul 16, 2026
pulisher
Jul 16, 2026

Lilly to enter psychedelics field with $3.8B AtaiBeckley buy - FirstWord PHARMA

Jul 16, 2026
pulisher
Jul 16, 2026

Lilly to buy psychedelic-drug firm AtaiBeckley - Chemical & Engineering News

Jul 16, 2026
pulisher
Jul 16, 2026

Nasdaq slides as chip selloff drags Wall Street lower - Proactive financial news

Jul 16, 2026
pulisher
Jul 16, 2026

Recon: Lilly to buy psychedelic developer AtaiBeckley for up to $3.8B; FDA approves Merck’s novel cholesterol drug - RAPS

Jul 16, 2026
pulisher
Jul 16, 2026

Eli Lilly Buys AtaiBeckley in $3.8 Billion Deal - TradingView

Jul 16, 2026
pulisher
Jul 16, 2026

AtaiBeckley Soars as Eli Lilly Agrees to $2.8 Billion Buyout - TradingView

Jul 16, 2026
pulisher
Jul 16, 2026

Market movers: AtaiBeckley, UnitedHealth Group, Abbott Laboratories, Medicus Pharma… - Proactive financial news

Jul 16, 2026
pulisher
Jul 16, 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of AtaiBeckley Inc. (NASDAQ: ATAI) - Morningstar

Jul 16, 2026
pulisher
Jul 16, 2026

AtaiBeckley: 'Hold'; Eli Lilly Acquisition For $2.8 Billion Adds To Its Neuroscience Pipeline - Seeking Alpha

Jul 16, 2026
pulisher
Jul 16, 2026

Eli Lilly Acquires Psychedelics Specialist AtaiBeckleyWhat Investors Should Know (LLY) - Seeking Alpha

Jul 16, 2026
pulisher
Jul 16, 2026

Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug - 24/7 Wall St.

Jul 16, 2026
pulisher
Jul 16, 2026

Lilly Expands Its Mind to Psychedelics With $2.8B AtaiBeckley Acquisition - MedCity News

Jul 16, 2026
pulisher
Jul 16, 2026

Pharma giant Eli Lilly enters psychedelics space with AtaiBeckley takeover - Mugglehead Investment Magazine

Jul 16, 2026
pulisher
Jul 16, 2026

Lilly to Buy Psychedelic Firm AtaiBeckley for Up to $3.8 Billion - marketscreener.com

Jul 16, 2026
pulisher
Jul 16, 2026

AtaiBeckley (ATAI) Sees 32.9% Surge in Stock Price - GuruFocus

Jul 16, 2026
pulisher
Jul 16, 2026

Eli Lilly Changed Depression Care With Prozac. Now It's Betting on Psychedelics with AtaiBeckley Acquisition - International Business Times

Jul 16, 2026
pulisher
Jul 16, 2026

Eli Lilly Is Buying AtaiBeckley in $2.8 Billion Deal. What It Means for LLY Stock - Barchart.com

Jul 16, 2026
pulisher
Jul 16, 2026

Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover - Pharmaceutical Technology

Jul 16, 2026
pulisher
Jul 16, 2026

Lilly acquiring firm developing psychedelic depression treatments for up to $3.8M - Inside INdiana Business

Jul 16, 2026
pulisher
Jul 16, 2026

Eli Lilly buys psychedelic drugs company AtaiBeckley for $3.8bn - The Times

Jul 16, 2026
pulisher
Jul 16, 2026

Latham & Watkins Represents AtaiBeckley in Sale to Lilly - Latham & Watkins LLP

Jul 16, 2026
pulisher
Jul 16, 2026

Why Is GH Research Stock Trading Higher on Thursday? - Benzinga

Jul 16, 2026
pulisher
Jul 16, 2026

Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics - BioPharma Dive

Jul 16, 2026
pulisher
Jul 16, 2026

Shareholder Alert: Ademi LLP investigates whether AtaiBeckley Inc. is obtaining a Fair Price for Public Shareholders - PR Newswire

Jul 16, 2026
pulisher
Jul 16, 2026

Lilly Strikes $3.8 Billion Deal for Psychedelic Drugmaker - Advisor Perspectives

Jul 16, 2026
pulisher
Jul 16, 2026

ATAI-dyed Lilly tees up in psychedelics, finds $3.8B fit - BioWorld News

Jul 16, 2026
pulisher
Jul 16, 2026

Eli Lilly Acquires AtaiBeckley for $3.8B - AllSci

Jul 16, 2026
pulisher
Jul 16, 2026

Eli Lilly agrees to $3.8B psychedelic buy - Axios

Jul 16, 2026
pulisher
Jul 16, 2026

Eli Lilly is acquiring psychedelic drug developer AtaiBeckley for $3.8 billion - Yahoo Finance Singapore

Jul 16, 2026
pulisher
Jul 16, 2026

Halper Sadeh LLC is Investigating Whether ATAI, CCRN, NUVL are Obtaining Fair Deals for their Shareholders - GlobeNewswire

Jul 16, 2026
pulisher
Jul 16, 2026

AtaiBeckley Inc (ATAI:UW): Stock Price, Quote and News - BNN Bloomberg

Jul 16, 2026
pulisher
Jul 16, 2026

Eli Lilly to acquire psychedelic drugmaker AtaiBeckley for $2.8 billion - qz.com

Jul 16, 2026
pulisher
Jul 16, 2026

Lilly enters psychedelic drug race with up to US$3.8 billion AtaiBeckley deal - BNN Bloomberg

Jul 16, 2026
pulisher
Jul 16, 2026

Eli Lilly deal to buy AtaiBeckley boosts psychedelic stocks - Seeking Alpha

Jul 16, 2026
pulisher
Jul 16, 2026

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal - KELO-AM

Jul 16, 2026
pulisher
Jul 16, 2026

Lilly confirms arrival of new psychedelic age with $3.8 billion AtaiBeckley buy - The Pharma Letter

Jul 16, 2026
pulisher
Jul 16, 2026

AtaiBeckley (ATAI) Surges Over 31% to Reach $7.05 - GuruFocus

Jul 16, 2026
pulisher
Jul 16, 2026

AtaiBeckley (NASDAQ: ATAI) stock jumps on Lilly deal as market discounts milestones - TechStock²

Jul 16, 2026
pulisher
Jul 16, 2026

Eli Lilly to Acquire AtaiBeckley for $2.8 Billion - Pharmaceutical Executive

Jul 16, 2026
pulisher
Jul 16, 2026

Eli Lilly and Company entered into an Agreement and Plan of Merger to acquire AtaiBeckley Inc. from Apeiron Investment Group Limited and others. - marketscreener.com

Jul 16, 2026
pulisher
Jul 16, 2026

Watch Lilly Buys Psychedelic Drugmaker AtaiBeckley for $3.8 Billion - Bloomberg.com

Jul 16, 2026
pulisher
Jul 16, 2026

Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday - Benzinga

Jul 16, 2026

Ataibeckley Inc Stock (ATAI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$116.65
price up icon 1.36%
$33.93
price down icon 2.75%
$63.15
price down icon 7.51%
$58.53
price up icon 3.94%
ONC ONC
$317.42
price up icon 1.98%
$283.15
price up icon 1.44%
Cap:     |  Volume (24h):